Shipments come on the heels of a severe flu season and record deaths in children.
The loss of activity is equivalent to 15% of the US population becoming completely immobile for 1 day.
Adult COVID-19 patients also infected with the flu are 4 times more likely to need mechanical ventilation and 2.4 times more likely to die.
The roadmap offers a powerful opportunity to leverage advances in vaccine science to better protect against influenza, including pandemic flu.
The Influenza Vaccines Roadmaps Initiative newsletter highlights recent news, research, and events pertaining to influenza vaccine R&D.
A database of novel vaccine candidates that are designed to provide broader and more durable protection against influenza viruses.
Help support our work on influenza. Advance the work of CIDRAP in public health preparedness and emerging infectious disease response.
Receive the latest infectious disease information.
The drug's prevention efficacy was 76% in the 450-mg group, 61% in the 300-mg group, and 58% in the 150-mg group.
Secondary bacterial pneumonia rates were significantly higher in the RSV group.
Studies tied oseltamivir to lower odds of death, shorter hospital stays, and lower rates of readmission, and onradivir and oseltamivir to speedier symptom relief.
A total of 11% of RSV patients experienced a cardiac event, abnormal heart rhythm, heart failure, or ischemic heart disease.
Wastewater levels for COVID-19 are low, while for influenza A and RSV they are very low.
The 10 new flu-related deaths in children bring the season's total to 226, the most since 2009-10.
Resistance developed in 10% of those treated with baloxavir.
The pediatric deaths push the season total to 216, surpassing last season's total of 207.
With increasing time since diagnosis, only the severe infections continued to cause symptoms.
Among clinicians with knowledge of guidelines, 62% recommended use.
